Roger Schindhelm

Roger Schindhelm

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MTMaarten E. Tushuizen
Maarten E. Tushuizen
MBMathijs C. Bunck
Mathijs C. Bunck
PPPetra J. Pouwels
Petra J. Pouwels
SBSaskia Bontemps
Saskia Bontemps
JWJan Hein T. van Waesberghe
Jan Hein T. van Waesberghe
MDMichaela Diamant
Michaela Diamant
OBJECTIVE—The purpose of this study was to determine whether an association exists between adiponectin and plaque composition in human coronary arteries.

1 April 2007 in Atherosclerosis
Verified
Journal Article
Closed access
RSRoger Schindhelm
Roger Schindhelm
JDJacqueline M. Dekker
Jacqueline M. Dekker
GNGiel Nijpels
Giel Nijpels
LBLex M. Bouter
Lex M. Bouter
CSCoen D.A. Stehouwer
Coen D.A. Stehouwer
MDMichaela Diamant
Michaela Diamant

11 July 2006 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
PDF file
RSRoger Schindhelm
Roger Schindhelm
MDMichaela Diamant
Michaela Diamant
JDJacqueline M. Dekker
Jacqueline M. Dekker
MTMaarten E. Tushuizen
Maarten E. Tushuizen
TTTom Teerlink
Tom Teerlink
RHRobert J. Heine
Robert J. Heine
For a long time, hepatic steatosis was believed to be a benign condition. Only recently, liver steatosis, also termednon‐alcoholic fatty liver disease(NAFLD), has gained much interest. In most cases of NAFLD, a condition regarded as the hepatic component of the metabolic syndrome, the enzyme alanine aminotransferase (ALT) is elevated and consequently has been used as a marker for NAFLD. More recently, several cross‐sectional and prospective studies have demonstrated associations of this liver enzyme with features of the metabolic syndrome and type 2 diabetes mellitus. This review discusses the biochemical and metabolic properties of ALT, its applicability as a marker of NAFLD and describes its possible role in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus and subsequent cardiovascular disease. In addition, treatment strategies to ameliorate NAFLD and the associated risks are discussed. Copyright © 2006 John Wiley & Sons, Ltd.

1 August 2009 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
RSRoger Schindhelm
Roger Schindhelm
LZLeonard P. van der Zwan
Leonard P. van der Zwan
TTTom Teerlink
Tom Teerlink
PSPeter G. Scheffer
Peter G. Scheffer
Background: Inflammation and oxidative stress are associated with atherosclerosis. Myeloperoxidase (MPO) is linked to both inflammation and oxidative stress by its location in leukocytes and its role in catalyzing the formation of oxidizing agents. Recent evidence suggests that MPO activity precipitates atherogenesis. Measurement of MPO in plasma may therefore contribute to cardiovascular disease (CVD) risk stratification. Content: Cross-sectional studies, case-control studies, and prospective-cohort studies investigating the relation between MPO and CVD have been evaluated. Differences in study populations, sample materials, sample handling, and assays were ascertained. Potential causal mechanisms linking MPO to accelerated atherosclerosis are discussed here. A majority of studies indicate that measurement of MPO in plasma was associated with improved CVD risk stratification above and beyond risk stratification results obtained with markers used in routine clinical practice. However, comparison of these epidemiological studies with regard to MPO and outcome is hampered because the reported MPO concentration depends on the assay method, sampling material, and preanalytical and analytical procedures. The link between MPO and CVD can, at least partly, be explained by MPO-dependent oxidation of LDL and HDL, subsequently leading to cholesterol accumulation in the arterial wall. Furthermore, MPO may reduce the bioavailability of nitric oxide, resulting in endothelial dysfunction. Finally, MPO destabilizes atherosclerotic plaques. Summary: Increasing evidence suggests that MPO is causally linked to atherosclerosis and its measurement may improve CVD risk estimation. Before MPO can be used in routine clinical practice, however, standardization of sampling and laboratory procedures is needed.

9 June 2005 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
RSRoger Schindhelm
Roger Schindhelm
MDM. Diamant
M. Diamant
SBStephan Bakker
Stephan Bakker
RDR. A. J. M. Van Dijk
R. A. J. M. Van Dijk
PSP. G. Scheffer
P. G. Scheffer
RHR. J. Heine
R. J. Heine

1 February 2013 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
ELErna Lenters-Westra
Erna Lenters-Westra
RSRoger Schindhelm
Roger Schindhelm
HBHenk J. Bilo
Henk J. Bilo
RSRobbert J. Slingerland
Robbert J. Slingerland